Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01033942 · ClinicalTrials.gov registry record · Phase 2
Pre-Exposure Prophylaxis in YMSM
A Phase 2 study of HIV, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 2
- Study locations
NCT01033942: Completed Phase 2 study of HIV, sponsored by University of North Carolina, Chapel Hill.
NCT01033942 is a Phase 2 study of HIV that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 68 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01033942, a Phase 2 study of HIV, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an exploratory mixed-methods research study that compares an efficacious behavioral HIV-prevention intervention (3MV) alone to the behavioral HIV-prevention intervention combined with a biomedical intervention (PrEP). After completing the 3MV behavioral intervention, participants will be randomly assigned to one of three study arms: 1) daily FTC/TDF as PrEP, 2) placebo pill control, or 3) "no pill" control. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks. Youth who decline to participate will be asked to complete a brief survey about their opinions on PrEP. Qualitative interviews will be completed with six study participants and the study coordinators at the end of the trial to explore further the issues of trial acceptability and feasibility. Finally, focus groups will be conducted to explore feasibility and acceptability issues with YMSM who meet all eligibility requirements of the study except for not being age 18 or older, but are at least 16 years of age.
Primary Outcome
This outcome measure looked at whether the actual number of study visits conducted by 24 weeks differed by treatment group over time.
Conditions Studied
Interventions
- DRUG Placebo
- BEHAVIORAL Many Men, Many Voices (3MV)
- DRUG coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP
Study Locations (2)
Illinois
- Ruth M Rothstein CORE Center/ John H Stroger Jr Hospital - Chicago
- Childrens Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
What the finished NCT01033942 record still lists
NCT01033942 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (85% lower).
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01033942 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01033942 about?
NCT01033942 is a clinical study titled "Pre-Exposure Prophylaxis in YMSM". This is an exploratory mixed-methods research study that compares an efficacious behavioral HIV-prevention intervention (3MV) alone to the behavioral HIV-prevention intervention combined with a biomedical intervention (PrEP). After completing the 3MV behavioral intervention, participants will be ran...
What is the current status of trial NCT01033942?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2009-08. Estimated completion is 2011-09.
What conditions does trial NCT01033942 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT01033942?
The interventions under investigation include: Placebo (DRUG), Many Men, Many Voices (3MV) (BEHAVIORAL), coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP (DRUG).
Who is sponsoring clinical trial NCT01033942?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01033942 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01033942's enrollment target sits among peer trials
68 194th of 303 higher than 110 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Improving Physical Ability and Cellular Senescence Elimination in HIV
RECRUITING · Phase 2
-
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
RECRUITING · Phase 2
-
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
RECRUITING · Phase 2
-
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia